The office building of the international biopharmaceutical company Astrazeneca.
CFOTO | Future publication | Getty pictures
Astrazeneca On Monday it said that it should invest 50 billion US dollars in the strengthening of its US manufacturing and research skills by 2030 and that the youngest pharmaceutical company is increasing its expenses in the USA according to the US trade tariffs.
The Anglo-Schwanze Biotech company, which was its headquarters in Cambridge, England, said that the “cornerstone” of commitment would be a new facility of several billion dollars to create its weight management and metabolic portfolio, including its oral GLP-1 adiposity pills.
The facility planned for the Commonwealth of Virginia is intended to be AstraZeneca's largest single manufacturing investment in the world and use “AI, automation and data analysis to optimize production,” said the company.
The latest financing will also expand research and development and cell therapy in Maryland, Massachusetts, California, Indiana and Texas and create “tens of thousands of jobs”, added AstraZeneca.
CEO Pascal Soriot said
Astrazeneca, which made international headlines through the development of one of the most important Covid 19 vaccines, has long prioritized the US market. The United States made up over 40% of the company's annual income in 2024.
In November, AstraZeneca announced a US dollar in US dollars shortly after the US presidential election. At the beginning of this month, the Times reported that the company could shift its list of London to the United States, which analysts say that they would be a big blow to the UK public markets.
Astrazeneca is the most valuable business listed in London's FTSE 100. The company refused to comment on the Times report.
Pharmaceutical companies increase the US expenses
The AstraZeneca financing announcement follows similar steps of global pharmaceutical company-Einchlich Novartis, Sanofi and Roche as well as the American US headquarters Eli Lilly and Johnson & Johnson-Die in recent months to increase their US investment in the demands of US President Donald Trump.
The industry is waiting for further clarity about the pharmaceutical management of the Trump administration with the end result of an investigation of the sector in section 232, which is due at the end of this month. A effort that US drug prices with the US drug prices paid by other countries.
At the beginning of this month, Trump proposed that the industry could be exposed to taxes of up to 200%with a short time from 12 to 18 months so that companies could move the production prosecutor. However, many companies and analysts have described the time frame as inadequate.
“As a rule, it is a horizon of three to four years for most medicines. We are working very hard to accelerate and show as soon as possible that we make the planned investments,” said Vas Narasimhan, CEO of Novartis, last week during a profit and added that the administration would lead to allowances.
Comments are closed.